<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">944</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2020-4-5-6-34-41</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Antipsychotic drugs market: issues of regional procurement</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Prozherina</surname><given-names>Yuliya</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RM Analytiсs Ltd.</aff><pub-date date-type="epub" iso-8601-date="2020-12-04" publication-format="electronic"><day>04</day><month>12</month><year>2020</year></pub-date><issue>4-6</issue><fpage>34</fpage><lpage>41</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2020,</copyright-statement><copyright-year>2020</copyright-year></permissions><abstract>Schizophrenia is one of the most common mental disorders characterized by combined positive and negative symptoms, behavioural and cognitive impairments that can lead to adverse social and economic outcomes. The disease is characterized by a chronic nature or course with frequent exacerbations and prolonged hospitalization, cumulative personality changes and a high level of disability, a higher rate of somatic concomitant diseases and a shorter life span of patients than the general population [1].</abstract><kwd-group xml:lang="en"><kwd>schizophrenia</kwd><kwd>prevalence</kwd><kwd>treatment</kwd><kwd>antipsychotics</kwd><kwd>market</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>шизофрения</kwd><kwd>распространенность</kwd><kwd>лечение</kwd><kwd>антипсихотики</kwd><kwd>рынок</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Зырянов С.К. и др. Фармакоэкономический анализ эффективности затрат современных атипичных антипсихотиков у больных шизофренией. Качественная клиническая практика. 2013;(2):18-32.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Здравоохранение в России - 2019. Федеральная служба Государственной статистики. Статистический сборник. 31.12.2019.170 с.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Иванец Н.Н., Анохина И.П., Винникова М.А. (ред.). Психофармакология наркологических заболеваний. В: Наркология: национальное руководство. М.: ГЭОТАР-Медиа; 2008. 719 с.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Якушева Е.Н. Система стандартных дневных доз лекарственных препаратов. Казанский медицинский журнал. 2008;89(5):701-703.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Сиволап Ю.П. Типичные и атипичные антипсихотики: насколько существенны различия? Журнал неврологии и психиатрии. 2018;(11):125-129. 2020;(4-5-6) | REMEDIUM</mixed-citation></ref></ref-list></back></article>
